AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25906560 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular acupuncture combined with acupuncture at trigone of urinary bladder
Number of subjects: 60
Study 25906560 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture (control group)
Number of subjects: 60
Study 23151532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 13709
Study 23151532 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 13709
Study 23151532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13709
Study 21597268 — intervention group
Group type: COMPARATOR
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 526
Study 21597268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic Holmium Laser Lithotripsy (URL)
Number of subjects: 526
Study 19422355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg i.v. bolus)
Number of subjects: 78
Study 19422355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 78
Study 19422355 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical control group
Number of subjects: 78
Study 16399963 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent to medication
Number of subjects: 184
Study 16399963 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent to medication
Number of subjects: 184
Study 15308995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 15603
Study 15308995 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 15603
Study 10654983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 168 microg twice daily (n = 51)
Number of subjects: 100
Study 10654983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 100
Study 10654983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP)
Number of subjects: 100
Study 10654983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9075038 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus propofol
Number of subjects: 203
Study 9075038 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus propofol
Number of subjects: 203
Study 8342393 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 0.018 IU/kg/day for 1 month followed by 0.036 IU/kg/day for 1 month
Number of subjects: 18
Study 8342393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of synthetic somatostatin
Number of subjects: 6
Study 2872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of secretin (280 pmol/kg‐h)
Number of subjects: 6
Study 2872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of cholecystokinin (pharmacological dose)
Number of subjects: 6
Study 2872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of gastric inhibitory polypeptide (GIP) (physiological range)
Number of subjects: 6
Study 31197249 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (omeprazole, amoxicillin, and clarithromycin; n=201)
Number of subjects: 404
Study 31197249 — intervention group
Group type: COMPARATOR
Intervention: Control group (omeprazole plus placebo; n=203)
Number of subjects: 404
Study 31197249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients (n=213)
Number of subjects: 404
Study 31197249 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body weight patients (n=167)
Number of subjects: 404
Study 31197249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increased baseline waist circumference (n=156)
Number of subjects: 404
Study 31197249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without increased baseline waist circumference (n=224)
Number of subjects: 404
Study 30124726 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Toreforant
Number of subjects: 62
Study 30124726 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Toreforant
Number of subjects: 62
Study 30124726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26795846 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (24-week double-blind placebo-controlled trial)
Number of subjects: 969
Study 26795846 — intervention group
Group type: COMPARATOR
Intervention: Usual care (placebo or medical treatment only)
Number of subjects: 969
Study 24933136 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention with health behavior monitoring, targeted messaging, and incentives for healthy goods and services
Number of subjects: 122
Study 24933136 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 122
Study 24933136 — intervention group
Group type: COMPARATOR
Intervention: American Cancer Society's Guide to Quitting Smoking online
Number of subjects: 122
Study 21919551 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage single-volume exchange transfusion (TSSV-ET)
Number of subjects: 104
Study 21919551 — intervention group
Group type: COMPARATOR
Intervention: Traditional single-stage double-volume exchange transfusion (SSDV-ET)
Number of subjects: 104
Study 20890191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin measured within 48 hrs of respiratory failure (Apn1)
Number of subjects: 175
Study 20890191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin increase at day 6 (Apn6)
Number of subjects: 175
Study 18343244 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg QD
Number of subjects: 249
Study 18343244 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg TID
Number of subjects: 249
Study 16194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10-20 mg/d) in group A (Scr 133-265 micromol/L)
Number of subjects: 168
Study 16194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10-20 mg/d) in group B1 (Scr 266-442 micromol/L)
Number of subjects: 168
Study 16194413 — intervention group
Group type: COMPARATOR
Intervention: Calcium-channel antagonist and/or beta-blocker and/or vasodilator in group B2 (control group)
Number of subjects: 168
Study 16194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril in group A
Number of subjects: 168
Study 16194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril in group B1
Number of subjects: 168
Study 16194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril in group A, group B1, and control group B2
Number of subjects: 168
Study 12598257 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose gentamicin (4 mg/kg)
Number of subjects: 70
Study 12598257 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest-dose gentamicin (1.2 mg/kg)
Number of subjects: 70
Study 12598257 — intervention group
Group type: COMPARATOR
Intervention: No gentamicin (NG)
Number of subjects: 70
Study 10374804 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education (self-care manual and two 2-hour seminars)
Number of subjects: 120
Study 10374804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-care education)
Number of subjects: 120
Study 8730613 — intervention group
Group type: COMPARATOR
Intervention: Energy intake estimated by weighted dietary inventory during days 1‐3 and 16‐18 of convalescence.
Number of subjects: 4
Study 8730613 — intervention group
Group type: COMPARATOR
Intervention: Energy intake of 261kJ/kg/24h (95% CL of 440kJ/kg/24h) meets the maintenance energy requirement (MER).
Number of subjects: 4
Study 8730613 — intervention group
Group type: COMPARATOR
Intervention: Linear relationship between B (y) and ME (x) given by y = 0.85x - 206.6 when B = 0, ME = MER.
Number of subjects: 4
Study 8470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 327
Study 8470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (PROG)
Number of subjects: 327
Study 8470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and Proguanil combination (CQ+PROG)
Number of subjects: 327
Study 2983910 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.26 mg/kg i.v.)
Number of subjects: 14
Study 2983910 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5.0 mg/kg i.v.)
Number of subjects: 14
Study 30245755 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudiezi injection
Number of subjects: 0
Study 30245755 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments
Number of subjects: 0
Study 27831712 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts and feelings intervention
Number of subjects: 0
Study 27831712 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement intervention
Number of subjects: 0
Study 27831712 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study 24903081 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training (n = 20)
Number of subjects: 31
Study 24903081 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 31
Study 22264332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy with therapist support (n = 44)
Number of subjects: 133
Study 22264332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy without therapist support (n = 45)
Number of subjects: 133
Study 22264332 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n = 44)
Number of subjects: 133
Study 20145666 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide milk (5 mg/day for 12 weeks, then 50 mg/day for 12 weeks)
Number of subjects: 89
Study 20145666 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk drink
Number of subjects: 89
Study 20145666 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide milk
Number of subjects: 89
Study 18176610 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) 100 mg/kg per day as a 6-h i.v. infusion until normalization of bilirubin, ALT and AST values.
Number of subjects: 160
Study 18176610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 160
Study 18176610 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC)
Number of subjects: 160
Study 15774591 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 200
Study 15774591 — intervention group
Group type: COMPARATOR
Intervention: Film-screen mammography (FSM)
Number of subjects: 200
Study 12526248 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days treatment
Number of subjects: 40
Study 12526248 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days treatment
Number of subjects: 40
Study 12526248 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 days treatment
Number of subjects: 40
Study 12526248 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 days treatment
Number of subjects: 40
Study 12526248 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days treatment (recommended duration)
Number of subjects: 40
Study 10486663 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's BP measurement
Number of subjects: 258
Study 10486663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse's BP measurement
Number of subjects: 258
Study 10486663 — intervention group
Group type: COMPARATOR
Intervention: Physician's decision not to modify treatment
Number of subjects: 258
Study 8595173 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with epidoxorubicin (EPI) 75 mg m‐2 on day 1, leucovorin (LV) 200 mg m‐2 on days 1‐3, and 5-fluorouracil (5‐FU) 450 mg m‐2 on days 1‐3, every 21 days for 7 months
Number of subjects: 103
Study 8595173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 103
Study 1910852 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin treatment for 8 weeks (group 2)
Number of subjects: 58
Study 1910852 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued digoxin treatment 5 weeks post-operation (group 3)
Number of subjects: 58
Study 1910852 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued digoxin treatment 3 weeks post-operation (group 4)
Number of subjects: 58
Study 1910852 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1) - no spontaneous atrial fibrillation
Number of subjects: 58
Study 6383135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 to 3 mg/kg total)
Number of subjects: 91
Study 6383135 — intervention group
Group type: COMPARATOR
Intervention: Bretylium Tosylate (10 to 30 mg/kg total)
Number of subjects: 91
Study 6383135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 to 3 mg/kg total) in patients on digitalis preparations
Number of subjects: 91
Study 6383135 — intervention group
Group type: COMPARATOR
Intervention: Bretylium Tosylate (10 to 30 mg/kg total) in patients on digitalis preparations
Number of subjects: 91
Study 31489826 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modelling
Number of subjects: 48
Study 31489826 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 48
Study 29953482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy (HYP) RE with 5 sets
Number of subjects: 24
Study 29953482 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength endurance (SE) RE with 5 sets
Number of subjects: 24
Study 29953482 — intervention group
Group type: COMPARATOR
Intervention: Low intensity (LI) RE with 5 sets
Number of subjects: 24
Study 29953482 — intervention group
Group type: COMPARATOR
Intervention: Maximum power (MAX) RE with 5 sets
Number of subjects: 24
Study 29953482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity (LI) RE with 10 sets
Number of subjects: 24
Study 29953482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy (HYP) RE with 10 sets
Number of subjects: 24
Study 29953482 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength endurance (SE) RE with 10 sets
Number of subjects: 24
Study 27013014 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell (PBSC) donation
Number of subjects: 526
Study 27013014 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow (BM) donation
Number of subjects: 526
Study 25287853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-based, patient-centered medication review prior to discharge from hospital
Number of subjects: 1626
Study 25287853 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 1626
Study 25287853 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1626
Study 22797934 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 82
Study 22797934 — intervention group
Group type: COMPARATOR
Intervention: Standard dose clopidogrel
Number of subjects: 82
Study 22797934 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-PRI
Number of subjects: 82
Study 22797934 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA
Number of subjects: 82
Study 22797934 — intervention group
Group type: EXPERIMENTAL
Intervention: MEA
Number of subjects: 82
Study 20627913 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months rifampin (4RIF)
Number of subjects: 847
Study 20627913 — intervention group
Group type: COMPARATOR
Intervention: 9 months isoniazid (9INH)
Number of subjects: 847
Study 17430214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell therapy
Number of subjects: 0
Study 17430214 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 15610952 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN‐alfa (PEG‐IFN‐alfa) 6 microg/kg/week subcutaneously for 8 weeks, followed by 3 microg/kg/week for a total of 5 years
Number of subjects: 17
Study 15610952 — intervention group
Group type: COMPARATOR
Intervention: non-treated controls
Number of subjects: 17
Study 12182803 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exploration of a virtual environment
Number of subjects: 75
Study 12182803 — intervention group
Group type: COMPARATOR
Intervention: Passive observation of the virtual environment
Number of subjects: 75
Study 12182803 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual training group
Number of subjects: 75
Study 12182803 — intervention group
Group type: EXPERIMENTAL
Intervention: Real training group
Number of subjects: 75
Study 12182803 — intervention group
Group type: COMPARATOR
Intervention: No training group
Number of subjects: 75
Study 9492968 — intervention group
Group type: EXPERIMENTAL
Intervention: Image source entry (forms entered using screen display of faxed forms)
Number of subjects: 1122
Study 9492968 — intervention group
Group type: COMPARATOR
Intervention: Double paper source entry (forms entered twice using paper forms)
Number of subjects: 1122
Study 9492968 — intervention group
Group type: EXPERIMENTAL
Intervention: Double image source entry (forms entered three times using image source)
Number of subjects: 1122
Study 12879525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 12879525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 2392791 — intervention group
Group type: EXPERIMENTAL
Intervention: System 22 Mizer with 50 mg pentamidine (3 ml fill)
Number of subjects: 9
Study 2392791 — intervention group
Group type: EXPERIMENTAL
Intervention: System 22 Mizer with 50 mg pentamidine (6 ml fill)
Number of subjects: 9
Study 2392791 — intervention group
Group type: COMPARATOR
Intervention: Respirgard II with 50 mg pentamidine (3 ml fill)
Number of subjects: 9
Study 2392791 — intervention group
Group type: COMPARATOR
Intervention: Respirgard II with 50 mg pentamidine (6 ml fill)
Number of subjects: 9
Study 2392791 — intervention group
Group type: EXPERIMENTAL
Intervention: System 22 Mizer with 150 mg pentamidine
Number of subjects: 9
Study 2392791 — intervention group
Group type: COMPARATOR
Intervention: Respirgard II with 150 mg pentamidine
Number of subjects: 9
Study 2392791 — intervention group
Group type: EXPERIMENTAL
Intervention: System 22 Mizer with increased volume of fill (from 3 to 6 ml)
Number of subjects: 9
Study 2392791 — intervention group
Group type: COMPARATOR
Intervention: Respirgard II with increased volume of fill (from 3 to 6 ml)
Number of subjects: 9
Study 2392791 — intervention group
Group type: EXPERIMENTAL
Intervention: System 22 Mizer
Number of subjects: 9
Study 2392791 — intervention group
Group type: COMPARATOR
Intervention: Respirgard II
Number of subjects: 9
Study 1271225 — intervention group
Group type: EXPERIMENTAL
Intervention: Control condition (subjects could determine frequency and duration of visits)
Number of subjects: 0
Study 1271225 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict condition (subjects informed of visit schedule but had no control)
Number of subjects: 0
Study 1271225 — intervention group
Group type: EXPERIMENTAL
Intervention: Random condition (subjects visited on a random schedule)
Number of subjects: 0
Study 1271225 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison group (not visited)
Number of subjects: 0
Study 31099216 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating needle therapy
Number of subjects: 72
Study 31099216 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 72
Study 26076014 — intervention group
Group type: EXPERIMENTAL
Intervention: IN0 (before the start of the session at the inlet blood line filled with rinsing solution)
Number of subjects: 13
Study 26076014 — intervention group
Group type: EXPERIMENTAL
Intervention: IN5 (5 min after the start at the inlet line filled with blood)
Number of subjects: 13
Study 26076014 — intervention group
Group type: EXPERIMENTAL
Intervention: OUT0 (before the start of the session at the outlet blood line)
Number of subjects: 13
Study 26076014 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Xa levels below 0.3 IU/mL at the end of the session
Number of subjects: 13
Study 26076014 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Xa above 0.3 IU/mL at the end of the session
Number of subjects: 13
Study 23482444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with manual and low-frequency electrical stimulation
Number of subjects: 32
Study 23482444 — intervention group
Group type: COMPARATOR
Intervention: Control group (meetings with a physical therapist twice a week for 10-13 weeks)
Number of subjects: 32
Study 23482444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 32
Study 23482444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 21441444 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/kg/min)
Number of subjects: 24
Study 21441444 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 24
Study 21441444 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 24
Study 21441444 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking endogenous GLP-1 receptor action
Number of subjects: 24
Study 19656148 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Number of subjects: 330
Study 19656148 — intervention group
Group type: EXPERIMENTAL
Intervention: Single balloon catheter
Number of subjects: 330
Study 19656148 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(2) gel (2 mg)
Number of subjects: 330
Study 17275744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active impedance threshold device (impedance 7 cmH2O)
Number of subjects: 22
Study 17275744 — intervention group
Group type: COMPARATOR
Intervention: Sham impedance threshold device (no inspiratory impedance)
Number of subjects: 22
Study 17275744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active impedance threshold device
Number of subjects: 22
Study 16197748 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 5.6% sodium hexametaphosphate
Number of subjects: 11
Study 16197748 — intervention group
Group type: COMPARATOR
Intervention: Negative control chewing gum
Number of subjects: 11
Study 16197748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate gum
Number of subjects: 11
Study 11730653 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy surgical group
Number of subjects: 74
Study 11730653 — intervention group
Group type: COMPARATOR
Intervention: Control group (fellow eyes)
Number of subjects: 74